Literature DB >> 9826368

Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue.

A Porgador1, H F Staats, Y Itoh, B L Kelsall.   

Abstract

We previously reported that cholera toxin (CT) was required as a mucosal adjuvant for the induction of peptide-specific cytotoxic T lymphocytes (CTL) following intranasal immunization with CTL epitope peptides (A. Porgador et al., J. Immunol. 158:834-841, 1997). The present study was performed to identify the site and the antigen-presenting cell (APC) population responsible for the presentation of intranasally administered CTL epitope peptide immunogens and to determine whether CT directly affects antigen presentation by these APCs. For these experiments, C57BL/6 mice were intranasally immunized with the ovalbumin H-2Kb-restricted CTL epitope SIINFEKL with or without CT. Cells were then isolated from the cervical lymph nodes (CLN) and the nasal mucosa-associated lymphoid tissue (NALT) and tested for the ability to stimulate the B3Z T-cell hybridoma, which recognizes SIINFEKL in association with H-2Kb. Dendritic cell (DC)-enriched CLN cells from mice immunized with peptide and CT or peptide only could stimulate B3Z cells, while DC-depleted CLN cells from either group were unable to stimulate B3Z cells. NALT cells of mice immunized with peptide and CT, but not with peptide alone, were able to efficiently stimulate B3Z hybridomas. Depletion of N418-positive DC from these NALT cells resulted in significant reduction of B3Z activation. Our results indicate that DC are the APC responsible for the presentation of CTL epitope peptides following intranasal immunization and that CT augments the ability of dendritic cells in the NALT, but not in the draining CLN, to present CLT epitope peptides. This finding suggests that CT acts locally as a mucosal adjuvant and that NALT DC are the predominant APC involved with the induction of immunity after intranasal immunization with peptide immunogens and CT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826368      PMCID: PMC108744     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).

Authors:  H F Staats; W G Nichols; T J Palker
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

3.  Cytokines and adherence molecules involved in spontaneous dendritic cell-lymphocyte clustering in skin afferent lymph.

Authors:  H Galkowska; U Wojewodzka; W L Olszewski
Journal:  Scand J Immunol       Date:  1995-09       Impact factor: 3.487

4.  Interleukin-1 beta and granulocyte-macrophage colony-stimulating factor mediate Langerhans cell maturation differently.

Authors:  H Ozawa; S Nakagawa; H Tagami; S Aiba
Journal:  J Invest Dermatol       Date:  1996-03       Impact factor: 8.551

5.  Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope.

Authors:  N A Staines; N Harper; F J Ward; V Malmström; R Holmdahl; S Bansal
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

6.  TAP1-deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity.

Authors:  J K Sandberg; B J Chambers; L Van Kaer; K Kärre; H G Ljunggren
Journal:  Eur J Immunol       Date:  1996-02       Impact factor: 5.532

7.  A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis.

Authors:  G Süss; K Shortman
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

8.  Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.

Authors:  J Tian; M A Atkinson; M Clare-Salzler; A Herschenfeld; T Forsthuber; P V Lehmann; D L Kaufman
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

9.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.

Authors:  B L Dickinson; J D Clements
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1.

Authors:  J A Roake; A S Rao; P J Morris; C P Larsen; D F Hankins; J M Austyn
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  21 in total

1.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

2.  Bordetella bronchiseptica persists in the nasal cavities of mice and triggers early delivery of dendritic cells in the lymph nodes draining the lower and upper respiratory tract.

Authors:  Pascale Gueirard; Patrick Ave; Anne-Marie Balazuc; Sabine Thiberge; Michel Huerre; Genevieve Milon; Nicole Guiso
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract.

Authors:  Javier Rangel-Moreno; Damian Carragher; Troy D Randall
Journal:  Inmunologia       Date:  2007

4.  In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii.

Authors:  Donata Medaglini; Annalisa Ciabattini; Anna Maria Cuppone; Caterina Costa; Susanna Ricci; Massimo Costalonga; Gianni Pozzi
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 5.  Mucosal vaccines: recent progress in understanding the natural barriers.

Authors:  Olga Borges; Filipa Lebre; Dulce Bento; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2009-12-01       Impact factor: 4.200

6.  Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.

Authors:  Carole Balmelli; Stéphane Demotz; Hans Acha-Orbea; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  Cholera toxin adjuvant promotes a balanced Th1/Th2/Th17 response independently of IL-12 and IL-17 by acting on Gsα in CD11b⁺ DCs.

Authors:  J Mattsson; K Schön; L Ekman; L Fahlén-Yrlid; U Yrlid; N Y Lycke
Journal:  Mucosal Immunol       Date:  2014-11-26       Impact factor: 7.313

8.  CC chemokine receptor 7 expression by effector/memory CD4+ T cells depends on antigen specificity and tissue localization during influenza A virus infection.

Authors:  Gudrun F Debes; Kerstin Bonhagen; Thorsten Wolff; Ute Kretschmer; Stefan Krautwald; Thomas Kamradt; Alf Hamann
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; George K Lewis
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; Timothy R Fouts; George K Lewis
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.